Guangzhou Wondfo BiotechLtd Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Zhongxiong Peng

Chief executive officer

CN¥2.6m

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	0.03%
Management average tenure	no data
Board average tenure	no data

Recent management updates

Recent updates

A Piece Of The Puzzle Missing From Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Share Price

Mar 27

There Are Reasons To Feel Uneasy About Guangzhou Wondfo BiotechLtd's (SZSE:300482) Returns On Capital

Feb 29

CEO

Zhongxiong Peng (49 yo)

no data

Tenure

CN¥2,577,900

Compensation

Mr. Zhongxiong Peng is General Manager of Guangzhou Wondfo Biotech Co.,Ltd. He was Deputy General Manager of Guangzhou Wondfo Biotech Co.,Ltd and serves as its Director. He was Deputy General Manager of Gu...

Guangzhou Wondfo BiotechLtd Management

Management criteria checks 0/4

Key information

Recent management updates

Insufficient new directors

Less than half of directors are independent

Recent updates

Investor sentiment improves as stock rises 20%

First quarter 2024 earnings released: EPS: CN¥0.49 (vs CN¥0.46 in 1Q 2023)

New minor risk - Shareholder dilution

Guangzhou Wondfo Biotech Co.,Ltd to Report Q1, 2024 Results on Apr 22, 2024

A Piece Of The Puzzle Missing From Guangzhou Wondfo Biotech Co.,Ltd's (SZSE:300482) Share Price

There Are Reasons To Feel Uneasy About Guangzhou Wondfo BiotechLtd's (SZSE:300482) Returns On Capital

Investor sentiment deteriorates as stock falls 15%

Guangzhou Wondfo Biotech Co.,Ltd to Report Fiscal Year 2023 Results on Apr 22, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Guangzhou Wondfo Biotech Co.,Ltd to Report Q3, 2023 Results on Oct 26, 2023

Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.62 in 2Q 2022)

Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) announces an Equity Buyback for CNY 50 million worth of its shares.

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 20% undervalued after recent price drop

Now 20% undervalued

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Now 23% undervalued

Price target decreased to CN¥60.42

Insufficient new directors

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.16 in 3Q 2021)

Investor sentiment improved over the past week

Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) announces an Equity Buyback for CNY 50 million worth of its shares.

Second quarter 2022 earnings released: EPS: CN¥0.62 (vs CN¥0.90 in 2Q 2021)

Guangzhou Wondfo Biotech Co.,Ltd announced that it expects to receive CNY 1 billion in funding

Guangzhou Wondfo Biotech Co.,Ltd Announces Cash Dividend, Payable on 14 June 2022

Guangzhou Wondfo Biotech Co.,Ltd Approves Cash Dividend for the Year 2021

Consensus revenue estimates increase by 34%

Less than half of directors are independent

Guangzhou Wondfo Biotech Co.,Ltd. Announces Profit Distribution Proposal for 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.27 in 3Q 2020)

Price target decreased to CN¥68.96

Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) announces an Equity Buyback for CNY 80 million worth of its shares.

Second quarter 2021 earnings released: EPS CN¥0.90 (vs CN¥0.79 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Guangzhou Wondfo Biotech Co.,Ltd Announces 2020 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 26 May 2021

First quarter 2021 earnings released: EPS CN¥0.46 (vs CN¥0.29 in 1Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥1.87 (vs CN¥1.14 in FY 2019)

Guangzhou Wondfo Biotech Co.,Ltd to Report Fiscal Year 2020 Results on Mar 31, 2021

Wondfo Rams Up Neutralizing Antibody, Antigen and PCR Tests to Address the Evolving Demands for COVID-19 Testing Globally

New 90-day high: CN¥95.02

New 90-day high: CN¥90.79

Investor sentiment improved over the past week

New 90-day low: CN¥74.05

Third quarter earnings released

New 90-day low: CN¥81.99

New 90-day low: CN¥83.05

New 90-day low - CN¥84.82

First half earnings released

Guangzhou Wondfo Biotech Co.,Ltd to Report First Half, 2020 Results on Aug 28, 2020

CEO

Tenure

Compensation